AstraZeneca has opened its first U.S.-operated cell therapy manufacturing facility in Rockville, Maryland, as part of its ...

AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...

Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the ...

AstraZeneca ( AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on ...

Find insight on AstraZeneca, Hartalega and more in the latest Market Talks covering the health care sector.

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

AstraZeneca CEO Pascal Soriot joins Morning Brief to discuss the outlook for the company and outlines AstraZeneca's plans to expand manufacturing and R&D operations in the US To watch more expert ...

Sir Pascal Soriot, AstraZeneca’s chief executive, said governments could “decide to not spend” on new medicines, but “then the jobs and the investments will go elsewhere”. He said ...

Pascal Soriot said innovation in pharmaceuticals ‘has mostly been funded by the US’ as he doubled down on plans to grow the business in America – which already accounts for 40 per cent of ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...